title: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults.
abstract: In patients with multiple myeloma, despite a major reduction of bone pain achieved with chemotherapy, skeletal disease continues to progress. The effects of clodronate, an inhibitor of osteoclastic bone resorption, are evaluated on the natural history of skeletal disease in patients with newly diagnosed multiple myeloma. Within the framework of the VIth MRC Multiple Myeloma Trial, 536 patients (218 women, 318 men) with recently diagnosed multiple myeloma were randomized to receive either clodronate 1600 mg daily (n=264) or an outwardly identical placebo (n=272) in addition to chemotherapy. Treatment with clodronate was associated with a 50% decrease in the proportion of patients with severe hypercalcaemia (5.1% v 10.1%, P=0.06) and a similar reduction in reported non-vertebral fractures (6.8% v 13.2%, P=0.04). Fewer patients receiving clodronate sustained vertebral fractures after entry to the trial (38% v 55%, P=0.01) and patients also lost less height over 3 years compared to those receiving placebo (2.0 v 3.4 cm, P=0.01). Biochemical indices of bone turnover were significantly lower in patients receiving concomitant clodronate, both at plateau and at disease relapse. The frequencies of back pain and poor performance status were significantly lower at 24 months in clodronate than in placebo-treated patients (10.9% v 19.9%, P=0.05, and 18.3% v 30.5% P=0.03 respectively.) There was no statistically significant difference in survival between the clodronate and placebo treated patients. The study indicates that long-term oral clodronate slows the progression of skeletal disease in multiple myeloma and decreases the associated morbidity. Patients without overt skeletal disease at diagnosis were also found to benefit from clodronate, indicating that this treatment should be initiated as early in the course of the disease as possible.
authors.forename: E V
authors.initials: EV
authors.lastname: McCloskey
authors.forename: I C
authors.initials: IC
authors.lastname: MacLennan
authors.forename: M T
authors.initials: MT
authors.lastname: Drayson
authors.forename: C
authors.initials: C
authors.lastname: Chapman
authors.forename: J
authors.initials: J
authors.lastname: Dunn
authors.forename: J A
authors.initials: JA
authors.lastname: Kanis
mesh_terms: D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects / Q000627:therapeutic use*; D001847:Bone Diseases / Q000517:prevention & control*; D002118:Calcium / Q000097:blood; D004002:Clodronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D006996:Hypocalcemia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D010146:Pain / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D018712:Analgesics, Non-Narcotic; D004002:Clodronic Acid; D002118:Calcium